Liquidia recently became the 30th drug manufacturer to restrict access to 340B pricing in the contract pharmacy setting.
Liquidia Becomes 30th Manufacturer to Limit Access to 340B Pricing in Contract Pharmacy Setting
Views
Drugmaker Liquidia will implement contract pharmacy restrictions for a single drug that has a still-pending new drug application (NDA). The [...]
Please Login or Become a Paid Subscriber to View this Content
If you are already a paid subscriber, please follow the steps below.